Why do some cancer cells survive treatment and allow the disease to return? This short video explains the role of low oxygen within tumours, introduces OCT1002’s potential to complement chemotherapy and radiotherapy, and highlights early research in a prostate cancer model.
OncoTherics welcomes discussions with investors and strategic partners interested in our unidirectional hypoxia-activated prodrug programmes.
Please leave your details below to arrange a conversation about the company and its investment opportunity.
Are you working on a project where OncoTherics' technology might be of help or would you like to collaborate in our research? Please provide your contact details so that we can include you on our contact list.